文章核心观点 - 公司将于2024年8月7日发布2024年第二季度财务业绩报告 [1] - 公司将于2024年8月7日上午9点东部时间举行网络直播会议,由CEO Michael Castagna和CFO Chris Prentiss参与 [2] - 公司专注于开发和商业化创新的吸入治疗产品和设备,以解决内分泌和罕见肺部疾病的严重未满足的医疗需求 [3][4] - 公司的核心技术包括干粉制剂和吸入设备,可以快速方便地将药物递送到肺部深部 [4] - 公司致力于让人们掌控自己的健康,享有生活的自由 [5]

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference ...

Investors might want to bet on MannKind (MNKD) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a cha ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is MannKind (MNKD) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.MannKind is a member of the Medical sector. This group includes 1025 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different groups, ...

Shares of MannKind (MNKD) have been strong performers lately, with the stock up 22.7% over the past month. The stock hit a new 52-week high of $5.93 in the previous session. MannKind has gained 60.2% since the start of the year compared to the 7% move for the Zacks Medical sector and the -0.8% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in an ...

Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17% with usual care and 24% had time-in-range (TIR) above 70% with no increased hypoglycemia compared with 13% with usual care More than 50% of subjects at the end of the study expressed an interest in continuing to use Afrezz ...

Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17% with usual care and 24% had time-in-range (TIR) above 70% with no increased hypoglycemia compared with 13% with usual care More than 50% of subjects at the end of the study expressed an interest in continuing to use Afrezz ...

17-week endpoint results comparing Afrezza® head-to-head with multiple daily injections (MDI) and insulin pumps INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with e ...

17-week endpoint results comparing Afrezza® head-to-head with multiple daily injections (MDI) and insulin pumps INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with ...

Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D space Non-cash deal includes royalty-free iSPERSE™ technology license in exchange for access to MannKind's Cricket® inhaler DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung d ...